Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$183.90M+186.35%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yongfeng Zhang
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,976
- Beta
- 0.92
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.17
Financials
Revenue
$183.90M+186.4%Net Income
$30.35M+680.2%EBITDA
$45.20M+375.2%Free Cash Flow
$42.73MEPS (diluted)
$0.67+737.5%Shares Outstanding (diluted)
44.23M-7.8%Operating Expenses
$53.74MCash & Debt
$290.12MReturn of Capital
$45.21MRevenue by Segment (annual)
$70.64MDividend per Share
$0.30Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $719.89M | $98.09M | $2.10 |
| 2024 | $731.97M | $159.52M | $3.29 |
| 2023 | $644.39M | $137.54M | $2.85 |
| 2022 | $498.99M | $91.39M | $1.88 |
| 2021 | $437.77M | $62.12M | $1.30 |
| 2020 | $349.85M | $1.40M | $0.03 |
| 2019 | $322.36M | $48.94M | $1.04 |
| 2018 | $294.67M | $-5.74M | $-0.12 |
| 2017 | $240.18M | $4.51M | $0.10 |
| 2016 | $255.16M | $10.53M | $0.23 |
| 2015 | $251.52M | $-2.79M | $-0.06 |
| 2014 | $210.46M | $-10.70M | $-0.25 |
| 2013 | $229.68M | $11.86M | $1.48 |
| 2012 | $204.32M | $18.09M | $2.26 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from AMPH's reported EPS growth of -0.6% a year over 13 years.
- EPS in 5 years
- $2.04
- Implied price
- $26.47
- Return from $25.43
- 0.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $13.16 — -48.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| -10.6% | -15.8% | -12.3% | -9.3% | -6.7% | -4.3% |
| -5.6% | -11.1% | -7.4% | -4.3% | -1.5% | 1.0% |
| -0.6% | -6.3% | -2.5% | 0.8% | 3.7% | 6.4% |
| 4.4% | -1.6% | 2.4% | 5.9% | 9.0% | 11.7% |
| 9.4% | 3.1% | 7.3% | 10.9% | 14.2% | 17.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsprnewswire.com·35d ago·Neutral
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET.
View source ↗ - Newszacks.com·39d ago·Neutral
3 Generic Drug Stocks to Watch Amid Improving Industry Trends The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
View source ↗ - Newszacks.com·53d ago·Neutral
New Strong Sell Stocks for August 14th AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.86 per share
Typical surprise +12.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.91 vs $0.62beat
- Thu, May 7$0.42 vs $0.70miss
- Thu, Feb 26$0.73 vs $0.90miss
- Thu, Nov 6$0.93 vs $0.77beat
- Thu, Aug 7$0.85 vs $0.71beat
- Wed, May 7$0.74 vs $0.66beat
Estimates and results for AMPH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AMPH officers and directors.
- Bought
- —
- Sold
- $1.8m
0 trades
18 trades
- Peters William Jsold
- Zhou Rongsold
- Zhou Rongsold
- Prins Richard Ksold
- Peters William Jsold
- Zhou Rongsold
- Petersen Floyd F.sold
- Petersen Floyd F.sold
82 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AMPH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.